A strong stock as of late has been Rigel Pharmaceuticals (RIGL) . Shares have been marching higher, with the stock up 105.8% over the past month. The stock hit a new 52-week high of $43.72 in the previous session. Rigel has gained 146.7% since the start of the year compared to the -1.4% gain for the Zacks Medical sector and the 10.6% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus E ...

Company Overview - Armata Pharmaceuticals, Inc. (ARMP) is part of the Medical sector, which includes 978 individual stocks and currently holds a Zacks Sector Rank of 7 [2] - The company has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Metrics - Over the past 90 days, the Zacks Consensus Estimate for ARMP's full-year earnings has increased by 24.7%, reflecting improved analyst sentiment [4] - Year-to-date, ARMP has returned approximately 36.8%, significantly outperforming the average return of -4.5% for Medical companies [4] Industry Context - Armata Pharmaceuticals operates within the Medical - Biomedical and Genetics industry, which consists of 488 stocks and currently ranks 97 in the Zacks Industry Rank [6] - The average return for stocks in this industry is 3% year-to-date, indicating that ARMP is performing better than its peers [6] Comparative Analysis - Another notable stock in the Medical sector is Avadel (AVDL), which has returned 28.5% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5] - Avadel belongs to the Medical - Drugs industry, which has a current rank of 80 and has moved up by 8.3% year-to-date [6] Investment Outlook - Both Armata Pharmaceuticals and Avadel are highlighted as stocks that could continue their strong performance, making them of interest to investors in the Medical sector [7]

Company Performance - Plus Therapeutics reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.09, and showing improvement from a loss of $0.71 per share a year ago, resulting in an earnings surprise of +88.89% [1] - The company posted revenues of $1.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 18.24%, but showing an increase from year-ago revenues of $1.28 million [2] - Over the last four quarters, Plus has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Plus shares have declined approximately 50.1% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $2.21 million, and for the current fiscal year, it is -$0.55 on revenues of $7.16 million [7] Industry Outlook - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Company Performance - IGC Pharma, Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, representing an earnings surprise of +33.33% [1] - The company posted revenues of $0.33 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.61%, but showing an increase from $0.27 million year-over-year [2] - Over the last four quarters, IGC Pharma has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - IGC Pharma shares have increased by approximately 5.7% since the beginning of the year, compared to a 10% gain in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $0.49 million, and for the current fiscal year, it is -$0.11 on revenues of $1.5 million [7] Industry Context - The Medical - Drugs industry, to which IGC Pharma belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact IGC Pharma's stock performance [5][6]

Company Performance - Aquestive Therapeutics (AQST) has returned approximately 12.6% year-to-date, outperforming the Medical sector, which has returned an average of -4.9% [4] - The Zacks Consensus Estimate for AQST's full-year earnings has increased by 0.5% over the past 90 days, indicating improving analyst sentiment [3] Industry Ranking - Aquestive Therapeutics is part of the Medical - Drugs industry, which consists of 153 companies and currently ranks 84 in the Zacks Industry Rank [5] - The average return for the Medical - Drugs industry so far this year is 8.3%, suggesting that AQST is performing better than its industry peers [5] Sector Overview - The Medical sector includes 978 individual stocks and is currently ranked 8 in the Zacks Sector Rank, which evaluates 16 different sector groups [2] - Arbutus Biopharma (ABUS), another stock in the Medical sector, has returned 3.1% year-to-date and has a Zacks Rank of 2 (Buy) [4][5]

Group 1 - VYNE Therapeutics Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +43.48% [1] - The company posted revenues of $0.07 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31%, and a decline from $0.2 million in the same quarter last year [2] - VYNE Therapeutics shares have decreased by approximately 89.6% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $0.15 million, and for the current fiscal year, it is -$0.94 on revenues of $0.6 million [7] - The Medical - Drugs industry, to which VYNE Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - MediWound reported a quarterly loss of $1.23 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.55, marking an earnings surprise of -123.64% [1] - The company posted revenues of $5.71 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.89% and showing growth from $5.06 million a year ago [2] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.64 on revenues of $6.68 million, and for the current fiscal year, it is -$1.99 on revenues of $23.97 million [7] Stock Performance - MediWound shares have increased by approximately 5.3% since the beginning of the year, compared to a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Drugs industry is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +22.22%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.07, delivering no surprise. Over the last four quarters, the company has surpassed cons ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -12.20%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.35, delivering no surprise. There are no easy answers to this key question, ...

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.83 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +29.69%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $0.59, delivering a surprise of +18.06%. Over the last four quarters, the company ha ...